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What is the European Commission Initiative on Breast Cancer? | 5
The European Commission Initiative on Breast Cancer (ECIBC) 1 is an initiative 
led by the European Commission that aims to ensure and harmonise the quality 
of breast cancer services across European countries on a sustainable basis.2
1. http://ecibc.jrc.ec.europa.eu.
2. The ECIBC’s impact is foreseen to spread beyond the EU as it is expected to be implemented in the 28 EU Member 
States, EU candidate countries (Albania, Iceland, Montenegro, The former Yugoslav Republic of Macedonia, Serbia and 
Turkey), EU potential candidates (Bosnia and Herzegovina and Kosovo), and EFTA members (Iceland, Liechtenstein, 
Norway and Switzerland).
What is the European Commission Initiative 
on Breast Cancer?
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Breast cancer, the most commonly diagnosed cancer in Europe
According to WHO 2012 estimates, each year 2.6 million new cases of cancer are 
diagnosed in Europe (excluding non-melanoma skin cancers).3 Breast cancer is the 
most frequent one with 364000 new cases per year.
Each year in Europe, one woman out of 275 receives a diagnosis of breast cancer, 
making it by far the most frequently diagnosed cancer among women (28.8% of 
all newly diagnosed cancers).
Breast cancer, the leading cause of death from cancer in women in Europe
Not only breast cancer is the most frequently diagnosed but, with 91000 deaths 
each year in Europe, is also the first cause of death from cancer for women and the 
third in the overall population.
Health inequalities in Europe related to breast cancer
There are substantial differences in breast cancer incidence, prevalence, mortality 
and survival in Europe.3,4,5,6 For example in 2012, the estimated age-standardised 
mortality rate (number of women out of 100000 dying of breast cancer) ranged 
from 15 to 29 (almost the double!) across countries of EU-27. Although the higher 
 
3. Ferlay et al. (2013). Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012. European Jour-
nal of Cancer, 49(6):1374-1403 (http://www.sciencedirect.com/science/article/pii/S0959804913000075). WHO estimations 
for the EU-27 in 2012 are presented, as they are the most recent aggregated estimations which best apply to the geographical 
area covered by the ECIBC.
4. Allemani et al. (2010). Variation in ‘standard care’ for breast cancer across Europe: A EUROCARE-3 high resolution 
study. European Journal of Cancer, 46(9):1 528-1 536 (http://www.sciencedirect.com/science/article/pii/S095980491000119X).
5. De Angelis et al. (2014). Cancer survival in Europe 1999-2007 by country and age: results of EUROCARE-5–a popula-
tion-based study. The Lancet Oncology, 15(1):23-343 (http://www.sciencedirect.com/science/article/pii/S1470204513705461).
6. Council Conclusions on reducing the burden of cancer. Luxembourg, 10 June 2008 (http://www.eu2008.si/en/News_and_
Documents/Council_Conclusions/June/0609_EPSCO-cancer.pdf).
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mortality rates may reflect the higher incidence of breast cancer in some countries, 
in others they might be due to the lower survival of women with breast cancer, 
hence to health inequalities among countries.
Figure 1. Age-standardised incidence and mortality rates in Europe 2012: breast cancer 
(adopted from Ferlay et al., 2013).
These inequalities may be caused by several factors, such as differences in epide-
miology of other fatal diseases, genetics, socio-economic status, exposure to risk 
factors, health policies (e.g. presence/absence of screening programmes), or the 
effective delivery of cancer control measures, among these, appropriate breast 
cancer care services.
Differences in the quality of breast cancer services in Europe
Differences in the quality of healthcare services have been reported across Euro-
pean countries. Moreover, more than ten different quality assurance schemes of 
breast cancer services coexist in Europe: 7 to harmonise and improve the quality 
of care in breast cancer services in Europe a common set of benchmarking quality 
requirements is needed.
7. Report of a European survey on the organisation of breast cancer care services (https://ec.europa.eu/jrc/en/publication/eur-sci-
entific-and-technical-research-reports/report-european-survey-organisation-breast-cancer-care-services-supporting-information).
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In summary, there is room for tackling inequalities in cancer in Europe by ad-
dressing healthcare.8 Therefore, a coordinated action at European level is needed 
to ensure that all European citizens have access to cancer care services with an 
essential level of quality and safety.
8. Commission communication on action against cancer 2009 (http://ec.europa.eu/health/ph_information/dissemina-
tion/diseases/docs/com_2009_291.en.pdf).
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While it is up to national governments to organise healthcare and ensure that it is 
provided, the EU does not define health policies, nor the organisation and provi-
sion of health services and medical care.
The EU’s role is to support national policies by
• helping EU governments achieve shared objectives;
• generating economies of scale by pooling resources;
• helping EU countries tackle shared challenges–pandemics, chronic diseases or 
the impact of increased life expectancy on healthcare systems.9
With this spirit, in December 2003, the Council adopted the Council Recommen-
dation on cancer screening,10 which recommended population-based screening pro-
grammes for breast, cervical and colorectal cancers in accordance with European 
guidelines. The adoption of European guidelines on best practice was identified as 
key for ensuring the development of high quality cancer-screening programmes. 
Therefore, the European Commission coordinated the development of screening 
guidelines: for breast cancer the latest was the 4th edition of the European Guide-
lines for Quality Assurance in Breast Cancer Screening and Diagnosis,11 including best 
practices defined by consensus of experts.
In 2007 the Lisbon Treaty was signed (Consolidated Treaty of the EU)12 and included 
specific provisions on the health policy. According to Title XIV, Article 168, the 
Commission may promote cooperative actions particularly ‘to combat the major 
cross-border health scourge and take initiatives aiming at the establishment of 
9. https://europa.eu/european-union/topics/health_en.
10. http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2003:327:0034:0038:EN:PDF.
11. https://publications.europa.eu/en/publication-detail/-/publication/7945bf8d-fa10-4e88-a781-9a7c36cf3411.
12. http://eur-lex.europa.eu/legal-content/EN/TXT/?uri=OJ:C:2016:202:TOC.
What is the legal ground for the ECIBC?
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guidelines and indicators, the organisation of exchange of best practice, and the 
preparation of the necessary elements for periodic monitoring and evaluation 
and adopt incentive measures’.
In 2008, both the European Parliament Resolution 13 and the Council Conclusions on 
reducing the burden of cancer 14 called on the Commission ‘to support the develop-
ment of European accreditation/certification programmes in cancer screening, 
diagnosis and treatment based on European quality-assurance guidelines’. They 
further called on ‘to explore the potential for the development of voluntary Euro-
pean accreditation schemes for cancer screening and appropriate follow-up of 
lesions detected by screening, such as a European pilot accreditation scheme for 
breast cancer screening and follow-up based on the European guidelines for qual-
ity assurance in breast cancer screening and diagnosis’.
Other acts are also relevant to the framework of ECIBC:
• The Council Recommendation on Patient Safety: 15 the minimum requirements set 
by the Recommendation will have to be included in the ECIBC.
• The Directive on the application of patients’ rights in cross-border healthcare: 16 relevant 
both for patients’ safety aspects and for patients’ rights to transparent informa-
tion on performance of healthcare services across borders.
• The Regulation for Accreditation and Market Surveillance 17 and its implementation 
acts provide the legal basis for ensuring an officially recognised peer reviewing 
system for the ‘European accreditation/certification programmes’ developed 
upon the Council Conclusions.
13. http://www.europarl.europa.eu/sides/getDoc.do?pubRef=-//EP//TEXT+TA+P6-TA-2008-0121+0+DOC+XM-
L+V0//EN.
14. http://www.eu2008.si/en/News_and_Documents/Council_Conclusions/June/0609_EPSCO-cancer.pdf.
15. http://ec.europa.eu/health//sites/health/files/patient_safety/docs/council_2009_en.pdf.
16. http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2011:088:0045:0065:EN:PDF.
17. http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2008:218:0030:0047:en:PDF.
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General goal
Within the Commission’s actions on chronic diseases, ECIBC’s overall goal is 
to contribute to improve health and to reduce health inequalities in Europe by 
ensuring and improving the quality of breast cancer services.
Specific objectives
In order to contribute to the overall goal, ECIBC aims to achieve the following 
specific objectives:
Objective 1: To propose evidence-based recommendations on screening and care 
for breast cancer services in Europe
The ECIBC considers six processes along the breast cancer care pathway: 
Figure 2. General breast cancer care pathway.
Objective 1.1: To develop the European Guidelines for Breast Cancer Screening and 
Diagnosis (the European Breast Guidelines) based on new knowledge and evidence
Coordinated by the JRC, the European Breast Guidelines start from the work of the 
4th edition of the European Guidelines for Quality Assurance in Breast Cancer Screen-
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ing and Diagnosis (published in 2006).11 In line with 2008 Council conclusions, 
the European Breast Guidelines provide evidence-based recommendations for the 
screening and diagnostic processes of breast cancer services. They are developed 
with GRADE 18 and have a web-based format.
Objective 1.2: To create a platform of guidelines for breast cancer treatment, 
rehabilitation and follow-up
For the other processes of the breast cancer pathway than screening and diagnosis 
(see Figure 2), as well as all relevant horizontal aspects, JRC develops a web-based 
platform of evidence-based guidelines (‘Guidelines Platform’). This platform, to-
gether with the European Breast Guidelines, provides the evidence on which the 
requirements of the European QA scheme are built.
Figure 3. Breast cancer care processes covered by the European Breast Guidelines 
and the Guidelines Platform.
The guidelines to be evaluated for inclusion in the Platform are identified by a sys-
tematic search and a call to stakeholders for including also non-publicly available 
guidelines. The Guidelines Platform includes guidelines on breast cancer fulfilling 
AGREEII 19 criteria, plus the presence of a structural updating plan and of an iden-
tified contact person.
18. http://www.gradeworkinggroup.org.
19. http://www.agreetrust.org/agree-ii/.
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Beyond their use for the European QA scheme, the Guidelines Platform is intended 
to be a valuable resource available to the public but in particular to professionals, 
policy makers, researchers, and guidelines developers. The ultimate impact of the 
Guidelines Platform will be to contribute to the reduction of unnecessary variability 
in breast cancer services and hence contribute to improve the outcomes of breast 
cancer patients in terms of morbidity, mortality, and quality of life.
Objective 1.3: To propose a procedure to maintain the evidence-based 
recommendations for breast cancer services up-to-date in the long term
The JRC will define a methodology to assess the need for updating the European 
Breast Guidelines and to incorporate in them all breast cancer care processes. It will 
apply this approach to warrant that the European Breast Guidelines and the recom-
mendations collected in the Guidelines Platform are based on the best available and 
up-to-date evidence.
Figure 4. Guidelines (and overall ECIBC) lifecycle. 
Research gaps Development
Updating
Monitoring
Implementation dissemination
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Objective 2: To develop a voluntary European QA scheme for Breast Cancer 
Services based on the EU legislative framework on accreditation, as defined 
in the Regulation of the European Parliament and of the Council setting out 
the requirements for accreditation and market surveillance
The European QA scheme focus on requirements that are relevant to people. Certifi-
cation/accreditation along the European QA scheme will be voluntary. The scheme 
respects the autonomy of European countries while steering towards the harmo-
nisation and coordination of existing quality standards and of new ones where 
evidence should support them. The European QA scheme is synergic with already 
existing schemes in the countries while proposing a roadmap towards continuous 
improvement.
The European QA scheme includes a set of quality and safety requirements for 
breast cancer services in Europe. The factors considered to select the requirements/
indicators to be implemented are:
• quality potential, as derived by the pathway,
• relevance as derived from the most updated evidence-based guidelines (the 
Euro pean Breast Guidelines and the Guidelines Platform),
• relevant legislation,
• professional best practices,
• available data collections,
• organisational settings, and
• feedback from countries related to implementation needs.
The scheme is based on the European legal framework for accreditation,17 hence 
under harmonised peer supervision across all involved countries under the co-or-
dination of the European co-operation for Accreditation (EA);20 hence is poten-
tially usable by all countries associated to EA. The European QA scheme covers all 
 
20. http://www.european-accreditation.org.
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the healthcare processes of breast cancer care as reported in Figure 3. Before being 
made available to users, the scheme is tested for its robustness across a limited but 
significant number of services resuming the diversity of situations and settings.
In order to respect the variability of breast cancer care organisation across coun-
tries, the European QA scheme has a modular structure. A module is a distinct pro-
cess or aggregation of processes (e.g. screening and diagnosis) which falls under the 
responsibility of a single entity. As not always breast care is provided by one single 
entity, but by several which are administratively independent from each other, the 
European QA scheme allows for modular certification. The following breast cancer 
care modules may ask for certification:
• Screening (organised, population-based)–corresponding to the process screen-
ing, including or not including the process ‘diagnosis’ after positive screening 
events.
• Breast centre–corresponding to the processes: diagnosis, treatment, follow-up, 
rehabilitation and survivorship care, and palliative care.
• End-of-life care–corresponding to the process ‘palliative care’.
Three different scenarios for this modular approach in certification are foreseen:
• One module approach: one legal entity is responsible for the whole pathway, 
from screening to end-of-life care. No processes are outsourced.
• Two modules approach: one legal entity is responsible for screening (e.g. re-
gional authority) and another one is responsible for all (for all processes from 
treatment to end-of-life care (e.g. hospital). No processes are outsourced.
• Three modules approach: one legal entity is responsible for screening (e.g. re-
gional authority), another one is responsible for all processes from treatment to 
follow-up (e.g. hospital), and a third one covers end-of-life care (e.g. local home 
care service, or hospice).
For each approach, a comprehensive (i.e. ‘single site’) or network (e.g. multisite 
cancer centre) feature will be available in order to guarantee the maximum level of 
flexibility and adaptation to local characteristics. A schematic presentation of the 
three modules approach is given in Figure 5.
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Figure 5. Modular approach with three modules for the European QA scheme.
Objective 3: To develop a European template for training 
on digital breast screening
A template for training on digital breast screening is to be developed. It is directed 
towards two main profiles involved in screening programmes: radiologists and 
radiographers. The template is developed by (i) deriving it from existing templates 
and (ii) considering the countries’ legal frameworks for professionals licencing and 
competence.
To design an implementable training template that is respecting countries’ legal 
frameworks, the ECIBC carried out two parallel actions:
1. Carried out a thorough search for existing templates.
2. Launched a survey for receiving information on the content of the existing 
trainings and on the legislations in place.
It is meant to be a requirement for competence and training for professionals 
providing digital breast screening in the services adhering to the European QA 
scheme. It is being developed in coordination with countries and experts and the 
modalities for its deployment are being defined (e.g. e-learning platform + hands-
on training).
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If successful, the same methodology may be applied for developing training tem-
plates for other professional profiles covered by the European QA scheme.
Objective 4: To develop a long-term web hub hosting all the deliverables
The ECIBC web hub1 is the communication interface of the initiative towards all 
stakeholders. It is the gateway to retrieve the most updated information about the 
outputs and tools produced within ECIBC. Its development is coordinated by 
JRC which stays tuned with the stakeholders’ inputs.
For instance, a woman wishing to know whether she should attend breast cancer 
screening should be able to find on the ECIBC web hub a recommendation, the 
corresponding quality requirements for the service providing screening under the 
European QA scheme, and the list of screening services, with respective performance 
levels, that obtained the certification in the area of interest for her.
The web hub is user-friendly, adapted to the needs of persons as well as health 
professionals. Moreover the web hub provides a platform for collaboration and 
exchange for those stakeholders that are directly involved in ECIBC, such as the 
working groups developing the European Breast Guidelines and the European QA 
scheme. Moreover, the web hub may serve as an example for other initiatives tack-
ling other cancer types and health problems. More details can be found in the 
ECIBC web hub concept and feasibility study.21
21. http://ecibc.jrc.ec.europa.eu/documents/20181/22500/ECIBC+web+hub+concept+and+feasibility+study_Report.pdf.
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1. Greater confidence in breast cancer services
Citizens will receive clear information on what to expect when seeking care at 
breast cancer services certified by the European QA scheme. This can increase the 
confidence in the quality of breast cancer services in Europe.
Provision of clear and comprehensive information on the quality of breast can-
cer services is in line with the implementation of the directive on patients’ rights 
in cross-border healthcare (DIRECTIVE 2011/24/EU). The certification of breast 
cancer centres across countries by the European QA scheme will allow for compar-
ing breast cancer care within and across country boarders and thus help patients 
to make an informed decision on where to seek treatment.
2. Reduction of health inequalities in Europe
By improving the quality of breast cancer services in Europe, the ECIBC aims at 
contributing to reduce the burden of cancer and at decreasing the avoidable dif-
ferences in breast cancer incidence, prevalence, mortality and survival.
3. Effective implementation and updating of the evidence
The ECIBC model uses the European QA scheme to ensure, via its requirements, 
that evidence based recommendations provided by guidelines are implemented. 
This may reduce unnecessary variability in healthcare provision and outcomes. In 
addition, the continuous feedback from auditees and auditors within the European 
QA scheme is expected to foster the updating of the guidelines.
4. Model transferrable to other health problems
The ECIBC model is being developed as a ‘blueprint’ for other health problems. 
Given its modular nature, in case of success, the ECIBC model would be easily 
The FUTURE: Expected benefits
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transferred to other cancers or other diseases and healthcare areas, with the possi-
bility to develop one or more of its parts (the Guidelines, the QA scheme or both). 
In addition, the modules used to simplify the care models applied in Europe, can 
be considered also for other care pathways. Its extension to colorectal and cervical 
cancers is something to be considered.
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Figure 6. Policy responsibility and endorsement of European Breast Guidelines 
and European QA scheme.22
1. The Coordination Role
The European Commission coordinates ECIBC. In particular the Directorate- 
General Health and Food Safety (DG SANTE) owns the policy leadership in 
health-related topics, in particular the EU public health policy on cancer,23 while 
the Joint Research Centre (JRC), thanks to an agreement with DG SANTE, coor-
dinates the Initiative ensuring consistency, synchronisation and rigorous method-
ology for all its parts.
22. As described in the DG SANTE governance document (http://ec.europa.eu/health//sites/health/files/major_chron-
ic_diseases/docs/eibc_structure_2014_en.pdf).
23. http://ec.europa.eu/health/major_chronic_diseases/diseases/cancer_en.
ECIBC structure
Commission expert group on Cancer Control
(DG SANTE)
Sub-groups as required
(e.g. platform, web hub, etc.)
Scientific and technical responsibility
JRC
The Guidelines
Development Group (GDG)
The Quality Assurance Scheme
Development Group (QASDG)
ECIBC structure | 21
The Commission is the most appropriate Institution to coordinate this initiative as:
• it has the means to steer the initiative in the long-term, granting ECIBC’s sus-
tainability,
• it provides a neutral platform for bringing together a wide range of actors and 
stakeholders at EU level, thus granting ECIBC neutrality,
• it possesses the tools for granting transparency, such as taking into account 
stakeholders’ inputs, through calls for feedback. 
Several Commission services are involved in ECIBC pooling their resources and 
expertise to develop and implement this unique initiative that can change the 
face of breast cancer healthcare. Also other cancer-related activities (e.g. the Com-
mission expert group on Cancer Control24 and the Joint Action CanCon) are 
informed and required to contribute. The Commission expert group on Cancer 
Control is a forum for Member States and stakeholders to provide input into 
cancer policies at EU level. They review the ECBIC in order to guarantee its full 
compatibility and coordination with the overall EU policies on cancer.25
2. The Technical Role
2.1. Technical coordination
JRC coordinates the scientific, technical, organisational and administrative as-
pects of the work. JRC also provides the outsourced supports, the collaborating 
tools and logistics for the ECIBC working groups and other involved stakehold-
ers. JRC also ensures appropriate communication with other EC services and 
relevant working/expert groups and projects. 
24. http://ec.europa.eu/transparency/regexpert/index.cfm?do=groupDetail.groupDetail&groupID=3203&NewSearch=1& 
NewSearch=1.
25. The Commission expert group on Cancer Control, created by Commission decision of 3 June 2014 and repealing Deci-
sion 96/469/EC (http://ec.europa.eu/health//sites/health/files/major_chronic_diseases/docs/com2014_c167_05_en.pdf), 
assists DG SANTE in its policy responsibility in the cancer domain in the drawing up of legal instruments and policy 
documents, guidelines and recommendations on cancer control at the request of the Commission.
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2.2. The working groups
For the first two objectives of the initiative, two working groups, the ‘Guidelines 
Development Group’ (GDG) and the ‘Quality Assurance Scheme Develop-
ment Group’ (QASDG), were created in Autumn 2015 following a call for expres-
sion of interest organised by DG SANTE. The selection process followed the rules 
for establishing scientific and consultative groups in the European Union. The 
European Breast Guidelines and the European QA scheme will be developed with the 
support of the GDG and QASDG, respectively.
More working groups may be set up on demand to support or accomplish the 
remainder objectives of the initiative, e.g. the Guidelines Platform.
2.3. The outsourced technical teams
The JRC, in view of both sustainability and neutrality, outsources any necessary 
services according to the usual tendering procedures of the Commission.
In this line, an outsourced systematic review team, the Iberoamerican Cochrane 
Centre (CCIb),26 is supporting the GDG in performing systematic reviews and 
developing evidence-based recommendations; they are also contracted for eval-
uating the guidelines to be hosted in the Guidelines Platform. Moreover, the Euro-
pean co-operation for Accreditation (EA)20 has been contracted for providing 
support to the QASDG both in the development and in the piloting phase of the 
European QA scheme (and to ensure that all National Accreditation Bodies will be 
ready to run it once approved). IQ Healthcare,27 on the other hand, is supporting 
the QASDG in the methodology aspects of the definition of requirements and 
indicators.
Representatives of the outsourced technical teams are attending the relevant meet-
ings. In case of need of additional expertise, scientific advisors or external experts 
are appointed to provide their inputs in the meetings.
26. http://es.cochrane.org/home.
27. http://www.iqhealthcare.nl/en/.
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Observers (apart from Commission officials) cannot participate in the working 
group meetings. Observers may, however, join the ECIBC Plenaries, where rele-
vant achievements of both working groups are summarised and relevant scientific 
topics are discussed. 
2.4. Input of Member States, other European Countries and stakeholders
Member States, EFTA, candidate and interested countries, and other relevant 
stakeholders are invited to express their opinion and suggestions on activities per-
formed by the different working groups at various development stages of ECIBC. 
For instance they provide feedback on the scope of the guidelines and of the QA 
scheme, can submit documents (e.g. guidelines), etc.
2.4.1. The group of ECIBC National Contacts
The JRC has asked the 28 EU Member States plus other European Countries 
to nominate a National Contact as a focal point to represent each participating 
Country during the projects course. Delegates are required to provide their contri-
bution at various development stages of ECIBC. The continuous communication 
with the National Contacts is essential for ensuring that the ECIBC respects the 
countries’ perspectives and own healthcare and quality assurance set-ups through-
out the project thus providing the basis for the successful implementation of the 
European QA scheme.
2.4.2. Other stakeholders
Other relevant parties or individuals involved by ECIBC (experts, patient’s or-
ganisations, professional societies, industry, etc.) are invited to participate, for 
instance via the Calls for feedback organised for the key outputs of the Initiative.
3. External Peer-Review
JRC arranges peer review from external experts for the publication of the key de-
liverables of the project, for example, for the final version of the European Breast 
Guidelines.
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Person-centred approach
ECIBC promotes an approach that considers the needs, preferences and values of 
people using or being possible users of breast cancer services. For the work of ECIBC 
this implies that persons and patient advocates are actively involved in all stages of 
the development of ECIBC outputs (e.g. being members of GDG and QASDG).
Inclusive and multidisciplinary approach
JRC is making a great effort to foster networking 28 to involve in ECIBC all the 
profiles: Individuals from the key areas for the project are involved in the working 
groups, views of interested parties (entities and individuals) are being integrated 
via Calls for feedback, contributing in this way to ECIBC’s successful implemen-
tation hence to increase its impact.
Based on this cooperative approach, ECIBC brings together a wide range of actors 
at a European level, including healthcare users, experts, professionals, NGOs, 
patient groups, civil society representatives, the industry, policy makers and in-
volved countries’ representatives (ECIBC National Contacts).
Evidence-based methods
ECIBC applies rigorous methods based on the best available evidence. The re-
quirements of the European QA scheme will be based on recommendations that will 
rigorously consider their evidence base. The recommendations provided by the 
European Breast Guidelines will be developed according to rigorous methods (e.g. 
GRADE 18 when applicable), and therefore will be based on the systematic review 
of the evidence.
28. European Commission Initiative on Breast Cancer–ECIBC: Organisation of project guiding and support meetings: Meetings 
2011-2013 (https://ec.europa.eu/jrc/en/publication/eur-scientific-and-technical-research-reports/european-commission-ini-
tiative-breast-cancer-ecibc-organisation-project-guiding-and-support).
Working methods
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Transparent and explicit working modalities
The ECIBC working modalities promote transparency in different ways:
1. It follows the rules implemented by the Commission to enhance transparency 
for its experts groups. All profiles, declarations of interest and photos of GDG 
and QASDG members, list of the ECIBC National Contacts, the minutes of 
GDG and QASDG working groups meetings are published online in the web 
hub.
2. The state-of-art of ECIBC is continuously updated on the web hub. The deliv-
erables are being submitted to Calls for feedback and peer reviewing. The final 
outputs will be publicly available on the web hub and disseminated through 
publications.
3. The GRADE 18 approach is being followed to develop the healthcare recom-
mendations. It is a transparent and explicit approach to grading the quality of 
evidence and strength of recommendations in healthcare. Other explicit and 
transparent methods will be applied when GRADE 18 is not appropriate.
4. The requirements for the European QA scheme will be developed following a 
modified The RAND/UCLA Appropriateness Method.29 This implies that, in 
a structured and transparent consensus process, requirements will be selected 
for their relevance considering their evidence base and their feasibility to be 
implemented in all European countries. This consensus involves experts from 
all relevant fields of breast cancer care and patients and National Contacts (for 
the implementability aspects).
5. Outsourcing of services functional to the objectives are always being organised 
via public tenders following the most transparent rules for contracting services. 
This outsourcing part is important both for ensuring a competent, independent 
and timely support to the ECIBC working groups.
Independent approach
The scientific advice is independent of all commercial, private and national inter-
ests, and is derived from the scientific assessment of topics evaluated.
29. https://www.rand.org/content/dam/rand/pubs/monograph_reports/2011/MR1269.pdf.
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The ECIBC follows the European Commission rules on management of Con-
flict of Interest: the members of the working groups and other contributors are 
asked to act in their own personal capacity and this implies a careful balance be-
tween the scientific and objective expertise and the possible other interests both 
of financial and intellectual nature. To grant independence, the JRC not only 
collects and publishes the annual declarations and collects the specific-to-meet-
ing-declarations but, most important, evaluates and manages potential conflicting 
interests, e.g. by proposing abstentions from voting and decisions and including 
a summary of abstentions in the minutes of each meeting (made available on the 
ECIBC web hub).
Monitoring of progress
Annual reports are being submitted to DG SANTE and made publicly available. 
All actions, outputs, events related to the ECIBC are constantly made available 
to the public via the ECIBC web hub.
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The ECIBC framework model provides an optimised and potentially standard-
ised way of:
• translating from recommendations (guidelines) to requirements (QA scheme),
• navigating across different care processes along the whole care pathway,
• reducing duplication of effort and resources, and
• transparently involving stakeholders.
In addition, a long-term monitoring strategy of ECIBC impact is planned to be 
developed. It will include a set of processes and outcome indicators that will be 
defined by experts in this field, along with a description of data that need to be 
collected for estimation of each indicator. The respective indicators will be mon-
itored at breast cancer service or at population-based level and will be compared 
with an evidence-based desired level of performance (where applicable) or with 
a baseline value. The examples from best practice in this area will be followed, 
considering also the availability of data in different countries.
Life-cycle plan
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The Commission allocates a budget of 4000000 EUR to the JRC for activities 
on cancer, which include ECIBC. The JRC jointly contributes by providing a 
sustainable infrastructure and a dedicated team30 in charge of the development 
and implementation of ECIBC. For more detail: Commission Implementing Deci-
sion 2011/C 358/06.31
The first set of recommendations of the European Breast Guidelines were made 
available on the ECIBC web hub in 2016 and a new set is added in 2017.
Figure 7. ECIBC timeline.
30. http://ecibc.jrc.ec.europa.eu/ecibc-team.
31. http://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:32011D1208(01)&from=EN.
Budget and timeline
2015 2016 2017 2018 2019 2020
GDG QASDG
appointment
ECIBC web hub
European QA 
scheme scope
European Breast 
Guidelines scope
First set of 
recommendations 
on screening
More sets of 
recommendations
Guidelines 
Platform 
version 1
European QA 
scheme call 
for pilot
European Breast 
Guidelines
Digital screening 
e-learning 
platform
Guidelines 
Platform
European QA 
scheme 
available to all
ECIBC life-cycle 
piloting
European QA 
scheme
Europe Direct is a service to help you find answers to your questions about the European Union
Free phone number (*): 00 800 6 7 8 9 10 11
(*) Certain mobile telephone operators do not allow access to 00 800 numbers or these calls may be billed.
A great deal of additional information on the European Union is available on the Internet.
It can be accessed through the Europa server http://europa.eu
How to obtain EU publications
Our publications are available from EU Bookshop (http://publications.europa.eu/howto/index_en.htm),
where you can place an order with the sales agent of your choice.
The Publications Office has a worldwide network of sales agents.
You can obtain their contact details by sending a fax to (352) 29 29-42758.
KJ-N
A-28738-EN
-N
doi:10.2760/78078
ISBN 978-92-79-72125-0
JRC Mission
As the science and knowledge service 
of the European Commission, the Joint 
Research Centre’s mission is to support 
EU policies with independent evidence 
throughout the whole policy cycle.
  EU Science Hub
  ec.europa.eu/jrc
 @EU_ScienceHub
 EU Science Hub - Joint Research Centre
 Joint Research Centre
 EU Science Hub
